Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Progesterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Progesterone SCHEMBL8430168 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL13259536 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL7671 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL15224316 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL20342397 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL3932110 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL23568915 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL17750737 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL20409003 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL14848937 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120226044-A1 | Process for the preparation of 4-azasteroids | LONZA AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120226044-A1 | Process for the preparation of 4-azasteroids | LONZA AG (CH) | 2012-09-06 | — | — | US | disclosed |
| EP-1765848-B1 | PROCESS FOR THE PREPARATION OF 4-AZASTEROIDS | LONZA GROUP AG (CH) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226044-A1 | Process for the preparation of 4-azasteroids | HSD17B7, CYP4A11, HSD3B1 | PGR 504/4885CYP3A4 37/4885LMNA 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.